



# **Pharmaceutical policies for effective, accessible and resilient health systems**

**Information point:**

**- STAMP (14 March 2017)**

**Dr. Dimitrios Florinis, PhD, Policy Officer (SNE)  
Unit B1 Performance of national health systems  
Directorate General for Health and Food Safety**

# Pharmaceutical policies for effective, accessible and resilient systems

## Challenges:

- **Pharmaceutical spending** in the EU is on avg 15% of total health care expenditures and 1.5% of GDP. On top of this hospital medicines account 20-30% of hospital expenditure.
- **Health at Glance (2016): Wide variations** across MS, due to differences in volume, structure of consumption and pharmaceutical prices. Some increases in expenditure in 2014 again due to **certain high-cost medicines** (hepatitis C or oncological).
- Room for **efficiency gains** in pharmaceuticals and health technologies (both from supply and demand side).

# Pharmaceutical policies for effective, accessible and resilient systems.

## DG SANTE work:

- **EURIPID project** 2015- 2018 on improvements on medicines price information that MS are voluntarily exchanging (mid- term evaluation).
- Support to **OECD to study** the sustainability of access to innovative therapies (under preparation).
- Mandate to the **Expert Panel** on Effective Ways Investing in Health to provide opinions on specific matters (on-going; to deliver Q3 2017).
- Contributing to other processes i.e. **European Semester cycle**, the Structural Reform Support Service (SRSS) etc.

# 1. "EURIPID Project" 2015- 2018

- **Euripid Project** Grant No. 664317 "Statistical data for medicinal product pricing" (2015- 2018) **funded by Health Programme.**
- **Half- time:** all deliverables and milestones scheduled for the first half of the Project period **are in time.**
- Participation and feedback from **third parties and stakeholders.**
- **Future synergies** with **other EU databases** and information tools (i.e. art 57 DataBase P-V, EMVO, Eurostat etc).
- **Current discussion** on the **Good practices model** (basis of the forthcoming Guidance Document for the users) as well as necessary IT- development.
- Next meeting in **Stockholm** (26- 27 April 2017).

## 2. The OECD study on Sustainable Access to Innovative Therapies

### The current project:

- A **Prospective study** on the sustainability of pharmaceutical spending, a model on access and expenditure to generate scenarios in selected therapeutic areas.
- A **high level expert group** to comment on analytical work and policy options.
- Consultation/ **meetings with stakeholders** (open/ closed meetings- last one on the 5th December 2016)
- **Draft report** to be submitted to the Health Committee on 26- 27 June 2017.
- **Participants:** BE, FR, DE, NL, UK and 8 non-EU members.

## 2. The OECD study on Sustainable Access to Innovative Therapies

### Health Programme 2017

- Part of SANTE- OECD cooperation (agreement under preparation).
- Aim to provide a **platform for an exchange of information**, good practises on budget impact forecasting and **develop a tool** to help MS to built capacity and increase the bargain power when negotiating with industry, as part of increasing health systems resilience.
- Possible other areas to cover:
  - Option for **ad- hoc technical assistance** to all EU MS?
  - Comments and **suggestions from STAMP?**

### 3. Expert Panel work on *Innovative payment models for high-cost innovative medicines*

**Panel is asked** to provide Opinion on:

- existing frameworks for **innovative payment models**?
  - the importance of choosing **the right outcomes** and interpreting them?
  - the **role of RWD** and the use from the payers (ie for budget impact, post- launch evaluation and exit strategies)?
  - the scope for improving cooperation and **possible synergies** between the payers, HTA bodies and regulators at EU level?
- Opinion planned for Q3 2017: **to present and discuss in STAMP?**

## 4. Pharmaceutical policies for effective, accessible and resilient systems

### Under the EU Economic Governance:

- The EC Agenda on **Effective, Accessible and Resilient Health Systems** (2014 Communication) and the Joint EC/EPC Report on **Health Care Systems and Fiscal Sustainability** (October 2016).
- **2017 Country Reports**: Pharmaceutical related challenges are raised in **6 MS country reports** (this year consultation with MS).
- Possibility for Technical Assistance under **Structural Reform Support Programme (SRSP)** as soon this will be adopted (currently in co- decision).



# Thank you!

## ***European Commission***

### ***Public Health information:***

[http://ec.europa.eu/health/index\\_en.htm](http://ec.europa.eu/health/index_en.htm)

[http://ec.europa.eu/health/systems\\_performance\\_assessment/policy\\_en](http://ec.europa.eu/health/systems_performance_assessment/policy_en)

[http://ec.europa.eu/health/expert\\_panel/home\\_en](http://ec.europa.eu/health/expert_panel/home_en)

### ***EU Economic Governance:***

[https://ec.europa.eu/info/business-economy-euro/economic-and-fiscal-policy-coordination/eu-economic-governance-monitoring-prevention-correction\\_en](https://ec.europa.eu/info/business-economy-euro/economic-and-fiscal-policy-coordination/eu-economic-governance-monitoring-prevention-correction_en)

### ***Structural Reform Support Service:***

[https://ec.europa.eu/info/departments/structural-reform-support-service\\_en](https://ec.europa.eu/info/departments/structural-reform-support-service_en)